JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Search

Twist Bioscience Corp

Закрыт

СекторЗдравоохранение

63.31 1.54

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

62.92

Макс.

65.68

Ключевые показатели

By Trading Economics

Доход

-3.4M

-31M

Продажи

4.7M

104M

Рентабельность продаж

-29.419

Сотрудники

979

EBITDA

-3.2M

-24M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

-12.47% downside

Дивиденды

By Dow Jones

Следующий отчет о доходах

4 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.2B

3.8B

Предыдущая цена открытия

61.77

Предыдущая цена закрытия

63.31

Новостные настроения

By Acuity

50%

50%

179 / 348 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 апр. 2026 г., 00:00 UTC

Главные новостные события

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 апр. 2026 г., 23:33 UTC

Отчет

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 апр. 2026 г., 22:40 UTC

Отчет

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 апр. 2026 г., 22:10 UTC

Приобретения, слияния, поглощения

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 апр. 2026 г., 21:11 UTC

Отчет

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 апр. 2026 г., 21:01 UTC

Отчет

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 апр. 2026 г., 23:46 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

22 апр. 2026 г., 23:46 UTC

Обсуждения рынка

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 апр. 2026 г., 23:34 UTC

Обсуждения рынка
Главные новостные события

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 апр. 2026 г., 23:16 UTC

Отчет

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 апр. 2026 г., 23:15 UTC

Отчет

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 апр. 2026 г., 22:54 UTC

Отчет

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 апр. 2026 г., 22:54 UTC

Отчет

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 апр. 2026 г., 22:52 UTC

Отчет

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 апр. 2026 г., 22:51 UTC

Отчет

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 апр. 2026 г., 22:31 UTC

Отчет

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 апр. 2026 г., 22:31 UTC

Отчет

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 апр. 2026 г., 22:30 UTC

Отчет

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 апр. 2026 г., 22:30 UTC

Отчет

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 апр. 2026 г., 22:29 UTC

Отчет

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 апр. 2026 г., 22:28 UTC

Отчет

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 апр. 2026 г., 22:28 UTC

Отчет

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 апр. 2026 г., 22:27 UTC

Отчет

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 апр. 2026 г., 22:06 UTC

Обсуждения рынка
Отчет

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 апр. 2026 г., 21:55 UTC

Приобретения, слияния, поглощения

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 апр. 2026 г., 21:47 UTC

Отчет

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 апр. 2026 г., 21:37 UTC

Отчет

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 апр. 2026 г., 21:34 UTC

Отчет

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 апр. 2026 г., 21:29 UTC

Отчет

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 апр. 2026 г., 21:20 UTC

Обсуждения рынка
Отчет

Tesla Expands Manufacturing to Chips -- Market Talk

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

-12.47% падение

Прогноз на 12 месяцев

Средняя 54.8 USD  -12.47%

Максимум 58 USD

Минимум 50 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

6

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

179 / 348Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat